Trial Profile
An Open-Label, Single-Arm, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Single and Multiple Doses of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Evinacumab (Primary) ; Evinacumab (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Proof of concept; Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 30 Jul 2018 Status changed from active, no longer recruiting to completed.
- 09 Jun 2018 Planned End Date changed from 30 Apr 2018 to 29 Jun 2018.
- 15 Mar 2018 Planned End Date changed from 16 Mar 2018 to 30 Apr 2018.